Muscle-Invasive Urothelial Carcinoma
Adjuvant nivolumab improves outcomes in high-risk urothelial cancer
SAN FRANCISCO — Adjuvant nivolumab improved outcomes compared with placebo for patients with high-risk muscle-invasive urothelial carcinoma, according to study results.
Adjuvant nivolumab significantly extends DFS in high-risk bladder cancer
Adjuvant nivolumab extended DFS compared with placebo among patients with high-risk, muscle invasive urothelial carcinoma, according to results of the phase 3 CheckMate 274 trial presented at Genitourinary Cancers Symposium.
Adjuvant nivolumab extends DFS in urothelial carcinoma subset
Adjuvant nivolumab significantly prolonged DFS compared with placebo for patients with high-risk, muscle-invasive urothelial carcinoma, according to topline data released by the agent’s manufacturer.
Adjuvant atezolizumab fails to extend DFS in high-risk urothelial carcinoma
Adjuvant atezolizumab failed to extend DFS compared with observation for patients with high-risk muscle-invasive urothelial carcinoma, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.